BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2014 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

We performed a 5-question survey of 40 oncologists from the US and the EU to gauge current prescribing practices for targeted therapies and gauge interest in new drug candidates for the treatment of breast cancer.

Drugs and drug candidates discussed: palbociclib, neratinib, Herceptin, Perjeta, Kadcyla, Tykerb, Afinitor. To purchase the Breast Cancer Pulse Survey, click the link at the top of the page.

For our disclosures, please read the BioMedTracker Research Standards.